Details

Last Funding Type

Series C

Last Funding Money Raised

¥700M

Industries

Biotechnology,Health Care

Founded date

Jan 1, 2016

Number Of Employee

51 - 100

Operating Status

Active

Developer of a genome sequencing technology. The company takes advantage of nanopores to sequence single nucleic acid molecules.Using innovative nanopore gene sequencing technology, it provides single-molecule sequencing capability with long reading length, real-time output of sequencing results, low single-running cost, small and convenient instrument, and cost-effective gene sequencing solution without complicated library preparation. It can directly detect the apparent modification of nucleic acids and expand the application of gene sequencing technology in cutting-edge biological research and clinical medicine such as instant diagnosis, metagenomics, epigenetics, RNA and transcriptomics.